Hormonal
Modulating reactive oxygen species (ROS) levels through antioxidant interventions does not consistently extend lifespan or delay age-related diseases, contradicting the mitochondrial free radical theory of ageing.
Do not rely on antioxidant supplements to extend your lifespan or prevent ageing. Current evidence from genetic models suggests that manipulating ROS levels does not consistently improve longevity and may interfere with natural stress-response mechanisms. Focus on proven interventions like dietary restriction or exercise, which may work by inducing mild, beneficial stress (mitohormesis) rather than simply neutralizing ROS.
interventions to modulate ROS levels in humans and animal models have not produced consistent results in terms of delaying disease progression and extending lifespan.
Why this rating
Based on multiple genetic mouse models, Drosophila, and C. elegans studies showing inconsistent or null effects of antioxidant manipulation on lifespan.
Source
The role of mitochondrial <scp>DNA</scp> mutations and free radicals in disease and ageing
Marie Lagouge et al. · Journal of Internal Medicine · 2013
DOI 10.1111/joim.12055
More from this paper
- Mitochondrial DNA (mtDNA) mutations accumulate with age primarily due to replication errors rather than oxidative damage, and while high levels of mutations can cause premature ageing, normal levels may not be the primary driver of ageing.Good
- Reactive oxygen species (ROS) function as essential signaling molecules that mediate stress responses and adaptation, rather than solely as damaging agents, a concept known as the 'gradual ROS response hypothesis'.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →